FUNDACION CIENTIFICA DE LA ASOCIACIÓN ESPANOLA CONTRA EL CANCER

Their core work

This is the scientific and research arm of Spain's principal cancer charity, AECC (Asociación Española Contra el Cáncer). Their core function is grantmaking and cancer research program management in Spain — they fund oncology research projects through national calls and channel Spanish funding into European transnational research networks. In H2020, they participate in the TRANSCAN ERA-NET series as a national co-funder, meaning they bring their own Spanish funding to joint European calls for translational cancer research proposals rather than receiving grants to perform bench research themselves. Their value in a consortium is access to Spain's national cancer research funding streams, institutional relationships with Spanish oncology researchers, and program management expertise in aligning national funding priorities with European research agendas.

What they specialise in

How they've shifted over time

The organization's H2020 trajectory follows a single continuous line: entry into the TRANSCAN network in 2015 and sustained commitment through the successor TRANSCAN-3 starting in 2021. No keyword data survives from the TRANSCAN-2 period, so direct topic comparison is not possible — but the thematic continuity between the two projects (both focused on aligning national cancer programmes) suggests deepening institutional embedding in European cancer research coordination rather than any strategic pivot. The richer keyword set in TRANSCAN-3 (translational research, prevention and treatment, national programme coordination) likely reflects improved data capture rather than a genuine topic shift, and signals growing specificity in how the foundation defines its European role.

They are deepening their role as Spain's representative national funder in the TRANSCAN pan-European cancer research network, with TRANSCAN-3 running to 2027 — making them a stable, long-term partner for any consortium needing Spanish cancer research program access or co-funding capacity.

How they like to work

This foundation exclusively joins consortia as a participant — they have never coordinated an H2020 project. Their participation in ERA-NET-Cofund projects places them inside very large, multi-country funding networks: 39 unique partners across 22 countries from just two projects, which is a structural feature of the ERA-NET model rather than unique network-building on their part. For a potential collaborator, this means they are an experienced, reliable consortium member with established working relationships across European national cancer funding agencies, but they are unlikely to take on project leadership roles.

Their network spans 39 unique partners across 22 countries, built entirely through two ERA-NET-Cofund projects — reflecting the inherently broad, multi-national structure of the TRANSCAN network rather than bilateral partnerships. Their connections are concentrated in national cancer research funding bodies and cancer charities across Europe.

What sets them apart

As the scientific foundation of Spain's largest cancer charity, they occupy a specific and rare position: a non-governmental national funding body that channels private fundraising into public-interest oncology research and connects Spanish national cancer priorities to European funding networks. For consortium builders, they offer something most academic or industrial partners cannot — a direct link into Spain's civil-society cancer research ecosystem, including relationships with clinical networks, patient organizations, and national oncology researchers who depend on AECC funding. Their participation signals credibility and patient-facing relevance to a cancer research consortium.

Highlights from their portfolio

• TRANSCAN-3
  Their largest H2020 grant (EUR 256,827), running until 2027, representing their most substantial and ongoing European commitment — and the clearest signal of their long-term role in pan-European cancer research coordination.
• TRANSCAN-2
  Their founding participation in the TRANSCAN ERA-NET network, establishing their position as Spain's civil-society representative in European translational cancer research alignment.